Characterization of the antibody response to pneumococcal glycoconjugates and the effect of heat-labile enterotoxin on IgG subclasses after intranasal immunization

被引:19
作者
Jakobsen, H
Adarna, BC
Schulz, D
Rappuoli, R
Jonsdottir, I [1 ]
机构
[1] Univ Hosp, Landspitali, Dept Immunol, IS-101 Reykjavik, Iceland
[2] Aventis Pasteur, Marcy Etoile, France
[3] Chiron SPA, Immunobiol Res Inst Siena, Siena, Italy
关键词
D O I
10.1086/320202
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The antibody response to pneumococcal glycoconjugate (Pnc) was characterized by analyzing pneumococcal polysaccharide (PPS)- and protein carrier-specific IgG subclass profiles and their relationship. Mice were immunized intranasally (inl) or subcutaneously (sc) with Pnc with mutants of Escherichia coli heat-labile enterotoxin, LT-R72 and LT-K63, as mucosal adjuvants. Subcutaneous immunization with Pnc alone induced predominantly IgG1, whereas native PPS administered sc induced very low IgG titers that were exclusively of the IgG3 subclass. Compared with sc immunization with Pnc alone, inl immunization with Pnc and LT mutants induced significantly higher systemic IgG2a, IgG3, and IgA antibodies to both PPS and the carrier, whereas the IgG1 titers were comparable. There also was a significant correlation between PPS- and protein carrier-specific antibody responses for all IgG subclasses. This demonstrates that LT mutants can be used to both enhance and modulate the antibody response to the PS moiety of glycoconjugate vaccines.
引用
收藏
页码:1494 / 1500
页数:7
相关论文
共 51 条
[1]   Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants [J].
Ahman, H ;
Kayhty, H ;
Tamminen, P ;
Vuorela, A ;
Malinoski, F ;
Eskola, J .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (02) :134-139
[2]  
AUSTRIAN R, 1964, ANN INTERN MED, V60, P769
[3]  
BARRETT DJ, 1986, CLIN EXP IMMUNOL, V63, P127
[4]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[5]   PNEUMOCOCCAL POLYSACCHARIDE VACCINE EFFICACY - AN EVALUATION OF CURRENT RECOMMENDATIONS [J].
BUTLER, JC ;
BREIMAN, RF ;
CAMPBELL, JF ;
LIPMAN, HB ;
BROOME, CV ;
FACKLAM, RR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (15) :1826-1831
[6]   CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies [J].
Chu, RS ;
McCool, T ;
Greenspan, NS ;
Schreiber, JR ;
Harding, CV .
INFECTION AND IMMUNITY, 2000, 68 (03) :1450-1456
[7]   Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens [J].
Dagan, R ;
Melamed, R ;
Zamir, O ;
Leroy, O .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (11) :1053-1059
[8]   Genetically derived toxoids for use as vaccines and adjuvants [J].
Del Giudice, G ;
Rappuoli, R .
VACCINE, 1999, 17 :S44-S52
[9]   Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of Hsai-Labile enterotoxin as a mucosal adjuvant [J].
DiTommaso, A ;
Saletti, G ;
Pizza, M ;
Rappuoli, R ;
Dougan, G ;
Abrignani, S ;
Douce, G ;
DeMagistris, M .
INFECTION AND IMMUNITY, 1996, 64 (03) :974-979
[10]   Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin [J].
Douce, G ;
Fontana, M ;
Pizza, M ;
Rappuoli, R ;
Dougan, G .
INFECTION AND IMMUNITY, 1997, 65 (07) :2821-2828